Hang Seng Index

Hansoh Pharmaceutical Group

A large Chinese innovative pharma company developing prescription drugs in oncology, CNS, and anti-infectives. Hang Seng Index constituent. Baseline node ahead of value-chain research; promoted to a full node once AI question demand is observed.

3692.HK Updated Jul 11, 2026 2 AI consumers· 1 recurring

Annual return · 2026-07-10'21-62.1%'22+1.1%'23-26.1%'24+55.2%'25+118.5%YTD-16.7%
Money in·
Hansoh Pharmaceutical Groupapprox. CN¥10.1B
Money out·

Financials & Segments

  • Total revenue · approx. CN¥10.1B (FY2023)
  • Segments · Oncology · Central nervous system · Anti-infective & metabolic

Revenue from

No refined links yet.

Pays to

No refined links yet.


← All companiesMarkdown · JSON

For information only, not investment advice. Content on this site is generated by AI from verified, cross-checked sources and may contain errors.

© 2026 Willow Investments, Inc.Company value-chain data · contact@willowinvt.com